- Coordinator
- Centre National De La Recherche Scientifique CNRS, France
- Runs
- 1 March 2026 to 28 February 2030
- Status
- Running
- EU funding
- €3.0m
- Total cost
- €3.0m
- Partners
- 6 organisations in 4 countries
- Type
- European Innovation Council
- Grant agreement
- 101259120
What the project is doing
In the project's own words, from its summary on CORDIS.
With 600,000 deaths per year, malaria remains the most devastating parasitic disease for humans. The efficiency of artemisinin-based combination therapy, the spearhead of malarial treatment, is now threatened by the development of drug resistant parasites displaying enhanced transmission potential to mosquitoes. Chagas disease, leishmaniasis and schistosomiasis are neglected tropical parasitic diseases that are considered as the greatest missed opportunities atop the priorities for WHO.
The FeROS project is based on the discovery of promising non-quinonoid chemotypes as precursors of 3-benzylmenadiones, with specific antiparasitic profiles depending on the substitution pattern. FeROS will follow convergent and complementary objectives: (i) to develop innovative and specific antiparasitic prodrugs in specific series of optimized drug-candidates to reach total cures in infected animal models for four human parasitic diseases, (ii) to extend the concept to animal health, (iii) to draw structure-activity relationships in in vitro and in vivo parasite assays, (iv) to build innovative chemical tools to visualize the release of active principles under ROS fluxes, in living parasites upon drug treatment, (v) to decipher the molecular and cellular mechanisms that underlie prodrug antiparasitic activities and selectivity.
FeROS is built on the multidisciplinary expertise of 7 laboratories from France, Belgium, Switzerland and USA. In an interdisciplinary approach, we will combine a large set of expertise, ranging from medicinal chemistry, physico(bio)chemistry, proteomics to parasite genetics and molecular and cellular parasitology to optimize the antiparasitic non-quinonoid prodrugs of 3-benzylmenadiones, to unravel their mode of action and take them to early clinical studies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Centre National De La Recherche Scientifique CNRS | Paris | France | Coordinator |
| Universiteit Antwerpen | Antwerpen | Belgium | Participant |
| Invenesis SARL | St-Blaise | Switzerland | Participant |
| Schweizerisches Tropen Und Public Health Institut | Allschwil | Switzerland | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Third party |
| University of Nebraska Medical Center | Omaha | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI